Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GALR3 | O60755 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459380 | 0.89 | GALR3 (0.49) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 | |
| SCHEMBL7265825 | 0.84 | GSK3B (0.48) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 | |
| SCHEMBL7015674 | 0.80 | SRD5A2 (0.59) | SRD5A2MAPK1CES2CES1GSK3B | |
| SCHEMBL4746218 | 0.79 | MAPK1 (0.63) | CYP3A4SRD5A2MAPK1CES2CES1 | |
| SCHEMBL7264321 | 0.77 | CES2 (0.53) | SRD5A2MAPK1CES2CES1HPGD | |
| SCHEMBL1460161 | 0.77 | SRD5A2 (0.50) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 | |
| SCHEMBL14706277 | 0.76 | GALR3 (0.43) | SMN1; SMN2GALR3CYP3A4CYP2C9NR2F2 | |
| SCHEMBL543118 | 0.74 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPK1HPGDTSHRNPC1 | |
| SCHEMBL11850279 | 0.74 | SRD5A2 (0.56) | SRD5A2MAPK1CES2CES1GSK3B | |
| SCHEMBL4288308 | 0.74 | HPGD (0.50) | CYP3A4MAPK1HPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2963023-B1 | PROCESS FOR PREPARING 5-AMINO-1, 2, 3-TRIAZOLE OROTATE DERIVATIVES | TACTICAL THERAPEUTICS INC (US) | 2018-04-18 | — | — | EP | claimed |
| EP-2963023-A1 | PROCESS FOR PREPARING 5-AMINO-1, 2, 3-TRIAZOLE OROTATE DERIVATIVES | Tactical Therapeutics Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-8912223-B2 | Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations | TACTICAL THERAPEUTICS INC (US) | 2014-12-16 | — | — | US | claimed |
| US-20140200247-A1 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations | KARMALI RASHIDA A (US) | 2014-07-17 | — | — | US | claimed |
| CN-119977778-A | Preparation method of carboxyamidotriazole intermediate | 广东银珠医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-112358451-B | Synthetic method of carboxyamidotriazole | 广东银珠医药科技有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-112358451-A | Synthetic method of carboxyamidotriazole | 广东银珠医药科技有限公司 | 2021-02-12 | — | — | CN | disclosed |
| EP-2963023-B1 | PROCESS FOR PREPARING 5-AMINO-1, 2, 3-TRIAZOLE OROTATE DERIVATIVES | TACTICAL THERAPEUTICS INC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2473051-B1 | NOVEL COMPOSITIONS AND PROCESSES FOR PREPARING 5-AMINO OR SUBSTITUTED AMINO 1,2,3-TRIAZOLES AND TRIAZOLE OROTATE FORMULATIONS | TACTICAL THERAPEUTICS INC (US) | 2016-02-10 | — | — | EP | disclosed |
| EP-2963023-A1 | PROCESS FOR PREPARING 5-AMINO-1, 2, 3-TRIAZOLE OROTATE DERIVATIVES | Tactical Therapeutics Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8912223-B2 | Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations | TACTICAL THERAPEUTICS INC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912223-B2 | Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations | TACTICAL THERAPEUTICS INC (US) | 2014-12-16 | — | — | US | disclosed |
| WO-2011028288-A1 | NOVEL COMPOSITIONS AND PROCESSES FOR PREPARING 5-AMINO OR SUBSTITUTED AMINO 1,2,3-TRIAZOLES AND TRIAZOLE OROTATE FORMULATIONS | Tactical Therapeutics, Inc (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110060142-A1 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | Tactical Therapeutics, Inc | 2011-03-10 | — | — | US | disclosed |
| US-20110060142-A1 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | Tactical Therapeutics, Inc | 2011-03-10 | — | — | US | disclosed |
| US-20110060142-A1 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | Tactical Therapeutics, Inc | 2011-03-10 | — | — | US | disclosed |
| EP-0304221-B1 | 5-amino or substituted amino 1,2,3-triazoles useful as antiproliferative agents | MERCK & CO INC (US) | 1994-02-16 | — | — | EP | disclosed |
| US-5045543-A | Treatment of cancer with high probability of metastasis | MERCK & CO., INC. (US) | 1991-09-03 | — | — | US | disclosed |
| US-4847257-A | PSORIASIS | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0304221-A2 | 5-amino or substituted amino 1,2,3-triazoles useful as antiproliferative agents | MERCK & CO. INC. (US) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060142-A1 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | MCL1, MALT1, MYD88 | SMN1; SMN2 1028/4885GALR3 489/4885CYP3A4 232/4885 |
| US-20140200247-A1 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations | MCL1, MALT1, ABAT | SMN1; SMN2 773/4885GALR3 467/4885CYP3A4 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.